Scientists probe fat particles to unlock heart disease secrets
NCT ID NCT00001154
First seen Jun 27, 2026 · Last updated Sep 09, 2026 · Updated 8 times
Summary
This study looked at how fat-carrying particles called lipoproteins work in healthy people and those with high cholesterol or other lipid disorders. Researchers injected tiny, safe amounts of radioactive lipoproteins to track them in the body. The goal was to better understand how these particles contribute to hardening of the arteries.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- labeled lipoproteins or apolipoproteins
- What this could lead to
- If successful, this research could help scientists better understand how fats in the blood contribute to heart disease, potentially guiding future treatments.
- What could go wrong
- This is an observational and metabolic study, not a treatment trial. It does not test a new therapy, so direct patient benefits are unlikely.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
759 people
The number who actually took part.
- Started
-
Sep 1976
- Lead sponsor
-
A government research agency
The lead sponsor is the US National Institutes of Health.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Dsylipidemia
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
* INCLUSION CRITERIA: Subjects with new and undefined dyslipidemia-particularly familial disorders with extreme phenotypes. Healthy normal volunteers - (18 years old or older) controls to investigate the formation of HDL for prebeta HDL. Euthyroid. EXCLUSION CRITERIA: Healthy control volunteers are initially screened for secondary causes of hyperlipidemia and are excluded if they have any clinically significant laboratory abnormality (i.e., liver disease, disease, kidney disease, endocrine disease,), chronic medical problems (i.e., hypertension, migraines, inflammatory bowel, hepatitis, HIV) or require any chronic medications (i.e., acne, asthma). The healthy control volunteers weight must fall within the current guidelines for ideal body weight. Pregnant women. Unwilling to follow metabolic diet. Allergic to iodine. Unable to sign consent form.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Dyslipidemia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Smoking and diet may shape cholesterol in mexican adults
- Triple-Drug cholesterol attack aims to strike within 72 hours of a heart attack
- Can a Once-Daily pill tame bad cholesterol?
- Smart pillbox aims to keep patients on track
- New pill aims to lower 'Bad' cholesterol: first human test begins
- Vitamin B3 supplement put to the test against psoriasis inflammation